{"id":"iproclozide","rwe":[{"pmid":"6794533","year":"1981","title":"[Treatment of certain refractory arterial hypertensions with a monoamine oxidase inhibitor].","finding":"","journal":"Archives des maladies du coeur et des vaisseaux","studyType":"Clinical Study"},{"pmid":"680506","year":"1978","title":"Iproclozide fulminant hepatitis. Possible role of enzyme induction.","finding":"","journal":"Gastroenterology","studyType":"Clinical Study"},{"pmid":"1270569","year":"1976","title":"Quantitative gas-liquid chromatography of iproniazid and iproclozide.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"},{"pmid":"1254681","year":"1976","title":"Improved column systems for gas-liquid chromatography of iproniazid and iproclozide.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"},{"pmid":"1217","year":"1975","title":"Identification and urinary excretion of p-chlorophenoxyacetamide, a metabolite of iproclozide, in humans.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"}],"tags":[{"label":"Monoamine Oxidase Inhibitors","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N06AF06","category":"atc"},{"label":"Active","category":"status"},{"label":"Depressive disorder","category":"indication"}],"phase":"phase_2","safety":{"drugInteractions":[{"url":"/drug/alpha/beta-agonists","drug":"Alpha/Beta Agonists","action":"Use caution","effect":"MAO Inhibitors may enhance the hypertensive effect of Alpha/Beta-Agonists","source":"DrugCentral","drugSlug":"alpha/beta-agonists"},{"url":"/drug/amphetamines","drug":"Amphetamines","action":"Use caution","effect":"MAO Inhibitors may enhance the hypertensive effect of amphetamines","source":"DrugCentral","drugSlug":"amphetamines"},{"url":"/drug/indirectly-acting-sympathomimetic-amines","drug":"Indirectly Acting Sympathomimetic Amines","action":"Contraindicated","effect":"potentially fatal hypertensive crisis","source":"DrugCentral","drugSlug":"indirectly-acting-sympathomimetic-amines"},{"url":"/drug/selective-serotonin-reuptake-inhibitors","drug":"Selective Serotonin Reuptake Inhibitors","action":"Contraindicated","effect":"serotonin syndrome","source":"DrugCentral","drugSlug":"selective-serotonin-reuptake-inhibitors"},{"url":"/drug/serotonin/norepinephrine-reuptake-inhibitors","drug":"Serotonin/Norepinephrine Reuptake Inhibitors","action":"Contraindicated","effect":"serotonin syndrome","source":"DrugCentral","drugSlug":"serotonin/norepinephrine-reuptake-inhibitors"},{"url":"/drug/tricyclic-antidepressants","drug":"Tricyclic Antidepressants","action":"Contraindicated","effect":"very toxic and sometimes fatal reactions the serotonin syndrome or similar","source":"DrugCentral","drugSlug":"tricyclic-antidepressants"},{"url":"/drug/buspirone","drug":"buspirone","action":"Use caution","effect":"May increase blood pressure","source":"DrugCentral","drugSlug":"buspirone"},{"url":"/drug/dextromethorphan","drug":"dextromethorphan","action":"Contraindicated","effect":"fatal/non-fatal reactions","source":"DrugCentral","drugSlug":"dextromethorphan"},{"url":"/drug/levodopa","drug":"levodopa","action":"Contraindicated","effect":"life-threatening hypertensive reaction","source":"DrugCentral","drugSlug":"levodopa"},{"url":"/drug/methyldopa","drug":"methyldopa","action":"Use caution","effect":"hypertension may occur","source":"DrugCentral","drugSlug":"methyldopa"},{"url":"/drug/mirtazapine","drug":"mirtazapine","action":"Contraindicated","effect":"Label warning","source":"DrugCentral","drugSlug":"mirtazapine"},{"url":"/drug/pethidine","drug":"pethidine","action":"Use caution","effect":"potentially life-threatening reaction","source":"DrugCentral","drugSlug":"pethidine"},{"url":"/drug/phenylephrine","drug":"phenylephrine","action":"Contraindicated","effect":"potentially fatal hypertensive crisis","source":"DrugCentral","drugSlug":"phenylephrine"},{"url":"/drug/tramadol","drug":"tramadol","action":"Use caution","effect":"serotonin syndrome","source":"DrugCentral","drugSlug":"tramadol"},{"url":"/drug/tryptophan","drug":"tryptophan","action":"Contraindicated","effect":"severe behavioural and neurological signs of toxicity","source":"DrugCentral","drugSlug":"tryptophan"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"iproclozid","offLabel":[],"synonyms":["iproclozide","iproclozid"],"timeline":[],"approvals":[],"brandName":"Iproclozid","ecosystem":[{"indication":"Depressive disorder","otherDrugs":[{"name":"amitriptyline","slug":"amitriptyline","company":"Astrazeneca"},{"name":"amoxapine","slug":"amoxapine","company":"Lederle"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"citalopram","slug":"citalopram","company":"Forest Labs"}],"globalPrevalence":280000000}],"mechanism":{"modality":"Small Molecule","drugClass":"Monoamine Oxidase Inhibitors","explanation":"Imagine your brain is a city with many roads (neurotransmitters) that help you feel happy or sad. Iproclozide is like a traffic cop that stops the garbage trucks (monoamine oxidase) from breaking down the roads, so more people (neurotransmitters) can use them, making you feel better.","oneSentence":"Iproclozide works by blocking the enzyme that breaks down certain neurotransmitters in the brain, allowing their levels to increase and improve mood.","technicalDetail":"Iproclozide acts as a reversible, non-selective inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), thereby increasing the levels of serotonin, norepinephrine, and dopamine in the synaptic cleft."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1479","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPROCLOZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:09:24.191723","biosimilars":[],"competitors":[{"drugName":"isocarboxazid","drugSlug":"isocarboxazid","fdaApproval":"1959-07-01","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"phenelzine","drugSlug":"phenelzine","fdaApproval":"1961-06-09","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tranylcypromine","drugSlug":"tranylcypromine","fdaApproval":"1961-02-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"iproclozide","indications":{"approved":[{"name":"Depressive disorder","source":"DrugCentral","snomedId":35489007,"regulator":"FDA","usPrevalence":21000000,"globalPrevalence":280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"isocarboxazid","brandName":"isocarboxazid","genericName":"isocarboxazid","approvalYear":"1959","relationship":"same-class"},{"drugId":"phenelzine","brandName":"phenelzine","genericName":"phenelzine","approvalYear":"1961","relationship":"same-class"},{"drugId":"tranylcypromine","brandName":"tranylcypromine","genericName":"tranylcypromine","approvalYear":"1961","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1II9D6CB3J","CHEBI":"CHEBI:134988","INN_ID":"1445","UMLSCUI":"C0063841","ChEMBL_ID":"CHEMBL91238","KEGG_DRUG":"D07338","DRUGBANK_ID":"DB09247","PUBCHEM_CID":"19063","MESH_SUPPLEMENTAL_RECORD_UI":"C010474"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06AF06","allCodes":["N06AF06"]},"biosimilarFilings":[],"recentPublications":[{"date":"1981 Jun","pmid":"6794533","title":"[Treatment of certain refractory arterial hypertensions with a monoamine oxidase inhibitor].","journal":"Archives des maladies du coeur et des vaisseaux"},{"date":"1978 Sep","pmid":"680506","title":"Iproclozide fulminant hepatitis. Possible role of enzyme induction.","journal":"Gastroenterology"},{"date":"1976 Jun","pmid":"1270569","title":"Quantitative gas-liquid chromatography of iproniazid and iproclozide.","journal":"Journal of chromatographic science"},{"date":"1976 Apr","pmid":"1254681","title":"Improved column systems for gas-liquid chromatography of iproniazid and iproclozide.","journal":"Journal of chromatographic science"},{"date":"1975 Nov-Dec","pmid":"1217","title":"Identification and urinary excretion of p-chlorophenoxyacetamide, a metabolite of iproclozide, in humans.","journal":"Drug metabolism and disposition: the biological fate of chemicals"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iproclozide is a small molecule Monoamine Oxidase Inhibitors (MAOIs) drug, originally developed by an unknown entity, but currently owned by an unspecified company. It is used to treat depressive disorder, although its commercial status and patent information are unknown. As a MAOI, it works by inhibiting the enzyme monoamine oxidase, which breaks down certain neurotransmitters in the brain, thereby increasing their levels and improving mood. The exact target of iproclozide is unknown, but it is believed to affect the levels of serotonin, norepinephrine, and dopamine. Further information on its pharmacokinetics and safety profile is not available.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}